• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of gutGutView this articleSubmit a manuscriptReceive email alertsContact usBMJ
Gut. Feb 2001; 48(2): 272–282.
PMCID: PMC1728206

Treatment of irritable bowel syndrome: a review of randomised controlled trials

Abstract

Irritable bowel syndrome (IBS) is a common chronic disorder that is associated with significant disability and health care costs. The purpose of this paper is to review and assess published randomised controlled trials examining the clinical effectiveness of interventions for IBS for 1987-1998. A literature search was conducted to identify randomised controlled trials of IBS treatments: 45 studies were identified that described randomised controlled trials and of these, six fulfilled all three criteria used to assess the quality of randomised controlled trials, as described by Jadad and colleagues.1 These criteria are: adequate description of randomisation, double blinding, and description of withdrawals and dropouts. It is concluded that there are few studies which offer convincing evidence of effectiveness in treating the IBS symptom complex. This review strongly suggests that future work should include well designed trials that: describe the randomisation method; use internationally approved diagnostic criteria; and are double blinded and placebo controlled. Clear well defined outcome measures are necessary. Inclusion of quality of life measures allows comparison between trials in different therapeutic areas. Conducting such studies will help to overcome some of the difficulties identified in this review.

Full Text

The Full Text of this article is available as a PDF (147K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996 Feb;17(1):1–12. [PubMed]
  • Camilleri M, Choi MG. Review article: irritable bowel syndrome. Aliment Pharmacol Ther. 1997 Feb;11(1):3–15. [PubMed]
  • Farthing MJ. Irritable bowel, irritable body, or irritable brain? BMJ. 1995 Jan 21;310(6973):171–175. [PMC free article] [PubMed]
  • Cook IJ, Irvine EJ, Campbell D, Shannon S, Reddy SN, Collins SM. Effect of dietary fiber on symptoms and rectosigmoid motility in patients with irritable bowel syndrome. A controlled, crossover study. Gastroenterology. 1990 Jan;98(1):66–72. [PubMed]
  • Lucey MR, Clark ML, Lowndes J, Dawson AM. Is bran efficacious in irritable bowel syndrome? A double blind placebo controlled crossover study. Gut. 1987 Feb;28(2):221–225. [PMC free article] [PubMed]
  • Prior A, Whorwell PJ. Double blind study of ispaghula in irritable bowel syndrome. Gut. 1987 Nov;28(11):1510–1513. [PMC free article] [PubMed]
  • Snook J, Shepherd HA. Bran supplementation in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 1994 Oct;8(5):511–514. [PubMed]
  • Toskes PP, Connery KL, Ritchey TW. Calcium polycarbophil compared with placebo in irritable bowel syndrome. Aliment Pharmacol Ther. 1993 Feb;7(1):87–92. [PubMed]
  • Tomás-Ridocci M, Añn R, Mínguez M, Zaragoza A, Ballester J, Benages A. Eficacia del Plantago ovata como regulador del tránsito intestinal. Estudio doble ciego comparativo frente a placebo. Rev Esp Enferm Dig. 1992 Jul;82(1):17–22. [PubMed]
  • Awad R, Dibildox M, Ortiz F. Irritable bowel syndrome treatment using pinaverium bromide as a calcium channel blocker. A randomized double-blind placebo-controlled trial. Acta Gastroenterol Latinoam. 1995;25(3):137–144. [PubMed]
  • Baldi F, Longanesi A, Blasi A, Monello S, Cestari R, Missale G, Corazziari E, Badiali G, Marzio L, Di Felice F, et al. Octylonium bromide in the treatment of the irritable bowel syndrome: a clinical-functional study. Hepatogastroenterology. 1992 Oct;39(5):392–395. [PubMed]
  • Centonze V, Imbimbo BP, Campanozzi F, Attolini E, Daniotti S, Albano O. Oral cimetropium bromide, a new antimuscarinic drug, for long-term treatment of irritable bowel syndrome. Am J Gastroenterol. 1988 Nov;83(11):1262–1266. [PubMed]
  • Dobrilla G, Imbimbo BP, Piazzi L, Bensi G. Longterm treatment of irritable bowel syndrome with cimetropium bromide: a double blind placebo controlled clinical trial. Gut. 1990 Mar;31(3):355–358. [PMC free article] [PubMed]
  • Lech Y, Olesen KM, Hey H, Rask-Pedersen E, Vilien M, Ostergaard O. Behandling af colon irritabile med pebermynteolie. En dobbeltblind undersøgelse med placebo. Ugeskr Laeger. 1988 Oct 3;150(40):2388–2389. [PubMed]
  • Liu JH, Chen GH, Yeh HZ, Huang CK, Poon SK. Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome: a prospective, randomized trial. J Gastroenterol. 1997 Dec;32(6):765–768. [PubMed]
  • Mollica G, Manno G. L'ottilonio bromuro+diazepam nel trattamento del colon irritabile. Studio controllato versus ottilonio bromuro. Clin Ter. 1992 Aug;141(8):129–134. [PubMed]
  • Passaretti S, Guslandi M, Imbimbo BP, Daniotti S, Tittobello A. Effects of cimetropium bromide on gastrointestinal transit time in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 1989 Jun;3(3):267–276. [PubMed]
  • Schäfer E, Ewe K. Behandlung des Colon irritabile. Wirksamkeit und Verträglichkeit von Buscopan plus, Buscopan, Paracetamol und Plazebo bei ambulanten Patienten mit Colon irritabile. Fortschr Med. 1990 Aug 30;108(25):488–492. [PubMed]
  • Shaw G, Srivastava ED, Sadlier M, Swann P, James JY, Rhodes J. Stress management for irritable bowel syndrome: a controlled trial. Digestion. 1991;50(1):36–42. [PubMed]
  • Van Outryve M, Mayeur S, Meeus MA, Rosillon D, Hendrickx B, Ceuppens M. A double-blind crossover comparison study of the safety and efficacy of mebeverine with mebeverine sustained release in the treatment of irritable bowel syndrome. J Clin Pharm Ther. 1995 Oct;20(5):277–282. [PubMed]
  • Chapman ND, Grillage MG, Mazumder R, Atkinson SN. A comparison of mebeverine with high-fibre dietary advice and mebeverine plus ispaghula in the treatment of irritable bowel syndrome: an open, prospectively randomised, parallel group study. Br J Clin Pract. 1990 Nov;44(11):461–466. [PubMed]
  • Misra SP, Thorat VK, Sachdev GK, Anand BS. Long-term treatment of irritable bowel syndrome: results of a randomized controlled trial. Q J Med. 1989 Oct;73(270):931–939. [PubMed]
  • Nayak AK, Karnad DR, Abraham P, Mistry FP. Metronidazole relieves symptoms in irritable bowel syndrome: the confusion with so-called 'chronic amebiasis'. Indian J Gastroenterol. 1997 Oct;16(4):137–139. [PubMed]
  • Villagrasa M, Boix J, Humbert P, Quer JC. Aleatory clinical study comparing otilonium bromide with a fiber-rich diet in the treatment of irritable bowel syndrome. Ital J Gastroenterol. 1991 Nov;23(8 Suppl 1):67–70. [PubMed]
  • Alevizos B, Christodoulou GN, Ioannidis C, Voulgari A, Mantidis A, Spiliadis C. The efficacy of amineptine in the treatment of depressive patients with irritable bowel syndrome. Clin Neuropharmacol. 1989;12 (Suppl 2):S66–S76. [PubMed]
  • Barbier JP, Dorf G, Gordin J, Krainik F, Neveu D, Parlier H, Richard P, Vitaux J, Fraitag B. Effet de l'association métiodure de buzépide-halopéridol dans le traitement des troubles fonctionnels intestinaux. Etude randomisée en double-aveugle contrôlée contre placebo. Ann Gastroenterol Hepatol (Paris) 1989 May;25(3):123–128. [PubMed]
  • Greenbaum DS, Mayle JE, Vanegeren LE, Jerome JA, Mayor JW, Greenbaum RB, Matson RW, Stein GE, Dean HA, Halvorsen NA, et al. Effects of desipramine on irritable bowel syndrome compared with atropine and placebo. Dig Dis Sci. 1987 Mar;32(3):257–266. [PubMed]
  • Tanum L, Malt UF. A new pharmacologic treatment of functional gastrointestinal disorder. A double-blind placebo-controlled study with mianserin. Scand J Gastroenterol. 1996 Apr;31(4):318–325. [PubMed]
  • Goldberg PA, Kamm MA, Setti-Carraro P, van der Sijp JR, Roth C. Modification of visceral sensitivity and pain in irritable bowel syndrome by 5-HT3 antagonism (ondansetron). Digestion. 1996 Nov-Dec;57(6):478–483. [PubMed]
  • Maxton DG, Morris J, Whorwell PJ. Selective 5-hydroxytryptamine antagonism: a role in irritable bowel syndrome and functional dyspepsia? Aliment Pharmacol Ther. 1996 Aug;10(4):595–599. [PubMed]
  • Steadman CJ, Talley NJ, Phillips SF, Zinsmeister AR. Selective 5-hydroxytryptamine type 3 receptor antagonism with ondansetron as treatment for diarrhea-predominant irritable bowel syndrome: a pilot study. Mayo Clin Proc. 1992 Aug;67(8):732–738. [PubMed]
  • Farup PG, Hovdenak N, Wetterhus S, Lange OJ, Hovde O, Trondstad R. The symptomatic effect of cisapride in patients with irritable bowel syndrome and constipation. Scand J Gastroenterol. 1998 Feb;33(2):128–131. [PubMed]
  • Schütze K, Brandstätter G, Dragosics B, Judmaier G, Hentschel E. Double-blind study of the effect of cisapride on constipation and abdominal discomfort as components of the irritable bowel syndrome. Aliment Pharmacol Ther. 1997 Apr;11(2):387–394. [PubMed]
  • Van Outryve M, Milo R, Toussaint J, Van Eeghem P. "Prokinetic" treatment of constipation-predominant irritable bowel syndrome: a placebo-controlled study of cisapride. J Clin Gastroenterol. 1991 Feb;13(1):49–57. [PubMed]
  • Efskind PS, Bernklev T, Vatn MH. A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome. Scand J Gastroenterol. 1996 May;31(5):463–468. [PubMed]
  • Halpern GM, Prindiville T, Blankenburg M, Hsia T, Gershwin ME. Treatment of irritable bowel syndrome with Lacteol Fort: a randomized, double-blind, cross-over trial. Am J Gastroenterol. 1996 Aug;91(8):1579–1585. [PubMed]
  • Hovdenak N. Loperamide treatment of the irritable bowel syndrome. Scand J Gastroenterol Suppl. 1987;130:81–84. [PubMed]
  • Lavö B, Stenstam M, Nielsen AL. Loperamide in treatment of irritable bowel syndrome--a double-blind placebo controlled study. Scand J Gastroenterol Suppl. 1987;130:77–80. [PubMed]
  • Lunardi C, Bambara LM, Biasi D, Cortina P, Peroli P, Nicolis F, Favari F, Pacor ML. Double-blind cross-over trial of oral sodium cromoglycate in patients with irritable bowel syndrome due to food intolerance. Clin Exp Allergy. 1991 Sep;21(5):569–572. [PubMed]
  • Prior A, Wilson KM, Whorwell PJ. Double-blind study of an alpha 2 agonist in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 1988 Dec;2(6):535–539. [PubMed]
  • Rodríguez Magallán A, Valadéz Velázquez T, Llorens Torres F, Sánchez Torres MI. Tratamiento del colon irritable con lidamidina y psicoterapia de apoyo. Rev Gastroenterol Mex. 1997 Jan-Mar;62(1):7–13. [PubMed]
  • Cann PA, Rovati LC, Smart HL, Spiller RC, Whorwell PJ. Loxiglumide, a CCK-A antagonist, in irritable bowel syndrome. A pilot multicenter clinical study. Ann N Y Acad Sci. 1994 Mar 23;713:449–450. [PubMed]
  • Dapoigny M, Abitbol JL, Fraitag B. Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome. A multicenter dose-response study. Dig Dis Sci. 1995 Oct;40(10):2244–2249. [PubMed]
  • Gade J, Thorn P. Paraghurt for patients with irritable bowel syndrome. A controlled clinical investigation from general practice. Scand J Prim Health Care. 1989 Mar;7(1):23–26. [PubMed]
  • Mathias JR, Clench MH, Reeves-Darby VG, Fox LM, Hsu PH, Roberts PH, Smith LL, Stiglich NJ. Effect of leuprolide acetate in patients with moderate to severe functional bowel disease. Double-blind, placebo-controlled study. Dig Dis Sci. 1994 Jun;39(6):1155–1162. [PubMed]
  • Mathias JR, Clench MH, Roberts PH, Reeves-Darby VG. Effect of leuprolide acetate in patients with functional bowel disease. Long-term follow-up after double-blind, placebo-controlled study. Dig Dis Sci. 1994 Jun;39(6):1163–1170. [PubMed]
  • Moher D, Jadad AR, Nichol G, Penman M, Tugwell P, Walsh S. Assessing the quality of randomized controlled trials: an annotated bibliography of scales and checklists. Control Clin Trials. 1995 Feb;16(1):62–73. [PubMed]
  • Clouse RE. Antidepressants for functional gastrointestinal syndromes. Dig Dis Sci. 1994 Nov;39(11):2352–2363. [PubMed]
  • Manning AP, Thompson WG, Heaton KW, Morris AF. Towards positive diagnosis of the irritable bowel. Br Med J. 1978 Sep 2;2(6138):653–654. [PMC free article] [PubMed]
  • Maxton DG, Morris JA, Whorwell PJ. Ranking of symptoms by patients with the irritable bowel syndrome. BMJ. 1989 Nov 4;299(6708):1138–1138. [PMC free article] [PubMed]
  • Pace F, Coremans G, Dapoigny M, Müller-Lissner SA, Smout A, Stockbruegger RW, Whorwell PJ. Therapy of irritable bowel syndrome--an overview. Digestion. 1995;56(5):433–442. [PubMed]
  • Pittler MH, Ernst E. Peppermint oil for irritable bowel syndrome: a critical review and metaanalysis. Am J Gastroenterol. 1998 Jul;93(7):1131–1135. [PubMed]
  • Poynard T, Naveau S, Mory B, Chaput JC. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 1994 Oct;8(5):499–510. [PubMed]

Articles from Gut are provided here courtesy of BMJ Group

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • MedGen
    MedGen
    Related information in MedGen
  • PubMed
    PubMed
    PubMed citations for these articles

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...